|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2004-5-7
|
|
pubmed:abstractText |
Imatinib (Glivec) has been established as a highly effective therapy for chronic myeloid leukemia and gastrointestinal tumors. The recommended daily dosage of 400-600 mg requires simultaneous intake of up to six of the current 100-mg capsules. Due to the need to swallow multiple capsules per dose, there is a potential negative impact on treatment adherence; therefore, a new imatinib 400-mg film-coated tablet has been developed. To improve dosing flexibility, particularly with regard to the pediatric population and the management of adverse events, a scored 100-mg film-coated tablet has also been introduced.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
53
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
433-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15132131-Adolescent,
pubmed-meshheading:15132131-Adult,
pubmed-meshheading:15132131-Aged,
pubmed-meshheading:15132131-Antineoplastic Agents,
pubmed-meshheading:15132131-Cross-Over Studies,
pubmed-meshheading:15132131-Female,
pubmed-meshheading:15132131-Humans,
pubmed-meshheading:15132131-Male,
pubmed-meshheading:15132131-Middle Aged,
pubmed-meshheading:15132131-Piperazines,
pubmed-meshheading:15132131-Pyrimidines,
pubmed-meshheading:15132131-Tablets,
pubmed-meshheading:15132131-Therapeutic Equivalency
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules.
|
|
pubmed:affiliation |
Novartis Oncology, Basel, Switzerland. zariana.nikolova@pharma.novartis.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
